Rustom R, Grime J S, Costigan M, Maltby P, Hughes A, Taylor W, Shenkin A, Critchley M, Bone J M
Department of Nuclear Medicine, Royal Liverpool University Hospital, UK.
Ren Fail. 1998 Mar;20(2):371-82. doi: 10.3109/08860229809045124.
Oral sodium bicarbonate (NaHCO3) is widely used to treat acidosis in patients with renal failure. However, no data are available in man on the effects on proximal renal tubular protein catabolism or markers of tubular injury. We have developed methods to allow such studies, and both increased tubular catabolism of 99mTc-labelled aprotinin (Apr*), as well as tubular damage were found in association with increased ammonia (NH3) excretion in patients with nephrotic range proteinuria. We now examine the effects of reducing renal ammoniogenesis, without altering proteinuria, using oral NaHCO3 in 11 patients with mild/moderate renal impairment and proteinuria. Renal tubular catabolism of Apr* was measured before and after NaHCO3 by renal imaging (Kidney uptake, K% of dose) and urinary excretion of free 99mTcO4- (metabolism, Met% of dose/h) over 26 h. Fractional degradation (Frac) was calculated from Met/K (/h). Fresh urine was also analyzed for NH3 excretion every fortnight from 6/52 before treatment. Total urinary N-acetyl-beta-D-glucose-aminidase (NAG) and the more tubulo-specific NAG "A2" were measured. 51CrEDTA clearance and 99mTc-MAG 3 TER were also assessed. After NaHCO3 Met over 26 h was significantly reduced (from 1.3 +/- 0.2% of dose/h to 0.9 +/- 0.1% dose/hr, p < 0.005), as was Frac of Apr* (from 0.06 +/- .006/h to 0.04 +/- 0.005/hr, p < 0.003). NH3 excretion also fell significantly (from 0.9 +/- 0.2 mmol/h to 0.2 +/- 0.05 mmol/h, p < 0.007), as did both total urinary NAG (from 169 mumol/24 h, 74-642 mumol/24 h to 79 mumol/ 24 h, 37-393 mumol/24 h, p < 0.01), and the NAG 'A2' isoenzyme (from 81.5 mumol/24 h, 20-472 mumol/24 h to 35.0 mumol/24 h, 6-388 mumol/24 h, p < 0.001). Proteinuria remained unaltered, and there was no change in blood pressure nor in glomerular haemodynamics. Oral NaHCO3 may thus pro-tect the proximal renal tubule and help delay renal disease progression.
口服碳酸氢钠(NaHCO₃)被广泛用于治疗肾衰竭患者的酸中毒。然而,关于其对近端肾小管蛋白分解代谢或肾小管损伤标志物影响的人体数据尚不存在。我们已开发出进行此类研究的方法,并且在肾病范围蛋白尿患者中发现,随着氨(NH₃)排泄增加,99mTc标记的抑肽酶(Apr*)的肾小管分解代谢增加以及肾小管损伤与之相关。我们现在使用口服NaHCO₃在11例轻度/中度肾功能损害和蛋白尿患者中研究在不改变蛋白尿的情况下减少肾脏氨生成的影响。通过肾脏成像(肾脏摄取,剂量的K%)和26小时内游离99mTcO₄⁻的尿排泄(代谢,剂量/小时的Met%)在服用NaHCO₃前后测量Apr的肾小管分解代谢。从Met/K(/小时)计算分数降解(Frac)。在治疗前的6/52期间,每两周还分析新鲜尿液中的NH₃排泄。测量总尿N-乙酰-β-D-葡萄糖苷酶(NAG)和更具肾小管特异性的NAG“A2”。还评估了51CrEDTA清除率和99mTc-MAG 3转运有效率(TER)。服用NaHCO₃后,26小时内的Met显著降低(从剂量/小时的1.3±0.2%降至0.9±0.1%剂量/小时,p<0.005),Apr的Frac也降低(从0.06±.006/小时降至0.04±0.005/小时,p<0.003)。NH₃排泄也显著下降(从0.9±0.2毫摩尔/小时降至0.2±0.05毫摩尔/小时,p<0.007),总尿NAG(从169微摩尔/24小时,74 - 642微摩尔/24小时降至79微摩尔/24小时,37 - 393微摩尔/24小时,p<0.01)和NAG“A2”同工酶(从81.5微摩尔/24小时,20 - 472微摩尔/24小时降至35.0微摩尔/24小时,6 - 388微摩尔/24小时,p<0.001)也下降。蛋白尿保持不变,血压和肾小球血流动力学也无变化。因此,口服NaHCO₃可能保护近端肾小管并有助于延缓肾脏疾病进展。